Citations

Showing 10 of 108081 citations.

Social cognition and behavioral outcomes in congenital heart disease: profiles and neuropsychiatric comorbidities
Ehrler, Melanie , Bellinger, David C., Cassidy, Adam R. , Newburger, Jane W. , Calderon, Johanna

Mayo Clinic

Child Neuropsychology | April 5, 2023 | Volume: 29 | Issue: 7 | Pages: 1041-1063

10.1080/09297049.2023.2196398 | PMID 37017255 Get It

Effects of a ketogenic and low‐fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer's disease
Neth, Bryan J. , West, Kiana , Zemlin, Jasmine , Rahman, Gibraan , Panitchpakdi, Morgan , Meehan, Michael J. , Blach, Colette , Schimmel, Leyla , Dorrestein, Pieter C. , Craft, Suzanne , Neth, Byran J. , Dilmore, Amanda Hazel , Martino, Cameron , Weldon, Kelly C. , Kaddurah‐Daouk, Rima , Knight, Rob

Mayo Clinic

Alzheimer's & Dementia | April 5, 2023 | Volume: 19 | Issue: 11 | Pages: 4805-4816

10.1002/alz.13007 | PMID 37017243 Get It

Abstract INTRODUCTION The ketogenic diet (KD) is an intriguing therapeutic candidate for Alzheimer's disease (AD) given its protective effects against metabolic dysregulation and seizures. Gut microbiota are essential for KD‐mediated neuroprotection against seizures as well as modulation of bile acids, which play a major role in cholesterol metabolism. These relationships motivated our analysis of gut microbiota and metabolites related to cognitive status following a controlled KD intervention compared with a low‐fat‐diet intervention. METHODS Prediabetic adults, either with mild cognitive impairment (MCI) or cognitively normal (CN), were placed on either a low‐fat American Heart Association diet or high‐fat modified Mediterranean KD (MMKD) for 6 weeks; then, after a 6‐week washout period, they crossed over to the alternate diet. We collected stool samples for shotgun metagenomics and untargeted metabolomics at five time points to investigate individuals’ microbiome and metabolome throughout the dietary interventions. RESULTS Participants with MCI on the MMKD had lower levels of GABA‐producing microbes Alistipes sp. CAG:514 and GABA, and higher levels of GABA‐regulating microbes Akkermansia muciniphila . MCI individuals with curcumin in their diet had lower levels of bile salt hydrolase‐containing microbes and an altered bile acid pool, suggesting reduced gut motility. DISCUSSION Our results suggest that the MMKD may benefit adults with MCI through modulation of GABA levels and gut‐transit time.
Workload assessment: Time to emanate from accurate conclusions instead of preconceived notions
Hasson, Dan , Okazawa, Susumu, Villaume, Karin , Hasson, Dan

Mayo Clinic

Journal of Occupational and Organizational Psychology | April 5, 2023 | Volume: 96 | Issue: 3 | Pages: 707-724

10.1111/joop.12436 Get It

Abstract Traditionally, assessments in psychosocial work environment research and practice utilize unidimensional response formats. This presupposes that higher or lower values are better or worse. Using unidimensional questions to assess multidimensional variables such as workload can be misleading. Two‐dimensional assessments using completing questions that indicate different aspects of the same construct may increase assessment precision and correctness. The current study aims to elucidate if and how two‐dimensional assessments of workload, that is, consistent ratings of high or low workload and level of satisfaction with it in repeated assessments, are related to outcomes in indicators of health, stress, well‐being and the psychosocial work environment, both cross‐sectionally and over time. 1284 study participants were followed for over 2 years. The results clearly and systematically demonstrated that often or rarely having too much to do, is not a reliable nor valid indicator of health, stress, well‐being and psychosocial work environment‐related outcomes. In contrast, the satisfaction dimension is systematically and consistently related to statistically significant and more pronounced differences in these outcomes. To properly help individuals at risk, both aspects of workload need to be assessed and accounted for. Whereas satisfaction is a better indicator of outcomes, the perceived workload magnitude is needed to intervene properly.
Pharmacogenetics of cardiovascular drugs
Saleh, Ateka, Pereira, Naveen L. , Al-Abcha, Abdullah, Al‐Abcha, Abdullah

Mayo Clinic

Current Opinion in Cardiology | April 5, 2023 | Volume: 38 | Issue: 3 | Pages: 207-214

10.1097/hco.0000000000001038 | PMID 37016993 Get It

Purpose of review Advances in pharmacogenomics have paved the way for personalized medicine. The purpose of this review is to summarize the background, rationale, and evidence for pharmacogenomics in cardiovascular medicine. Recent findings Randomized clinical trials have supported the role of a genotype-guided approach for antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary interventions. Additionally, there is increasing evidence supporting the association of certain genetic variants and risk of statin associated muscle symptoms. Furthermore, germline genetic variation is being used as a biomarker to target patients with specific therapy. Summary Pharmacogenomics has the potential to improve patient care by providing the right drug to the right patient and could guide the identification of novel drug therapies for cardiovascular disease.
Effects of an educational physical activity intervention in young women with newly diagnosed breast cancer: Findings from the Young and Strong Study
Ligibel, Jennifer A. , Barry, William T., Sella, Tal , Ruddy, Kathryn J. , Rosenberg, Shoshana M. , Emmons, Karen M. , Partridge, Ann H. , Emmons, Karen M. , Ruddy, Kathryn J , Rosenberg, Shoshana , Partridge, Ann H , Zheng, Yue , Greaney, Mary L.

Mayo Clinic

Cancer | April 5, 2023 | Volume: 129 | Issue: 14 | Pages: 2135-2143

10.1002/cncr.34779 | PMID 37016839 Get It

AbstractBackgroundObesity and inactivity are poor prognostic factors in breast cancer, but less is known regarding physical activity (PA) and weight patterns in young breast cancer survivors.MethodsThe Young and Strong Study was a cluster‐randomized trial evaluating education and support interventions for young women (age <45 years) with newly diagnosed breast cancer. Sites were randomized 1:1 to a Young Women's Intervention (YWI) or a contact‐time control physical activity intervention (PAI). Changes in PA and weight were compared between groups using general estimating equations to evaluate clustered binary and Gaussian data.ResultsA total of 467 patients enrolled between July 2012 and December 2013 across 54 sites. Median age at diagnosis was 40 years (range, 22–45). At baseline, median body mass index (BMI) was 25.4 kg/m2 (range, 16.1–61.1), and participants reported a median of 0 minutes (range, 0–2190) of moderate/vigorous PA/week. PA increased significantly over time in both groups (p < .001), with no difference between groups at any time point. BMI increased modestly but significantly (p < .001) over time in both groups. Provider attention to PA was observed in 74% of participants on PAI and 61% on YWI (p = .145) and correlated with PA at 12 months (median 100 min/week of PA in participants with provider attention to PA vs. 60 min/week in those without, p = .016).ConclusionsIn a cohort of young women with breast cancer, rates of obesity and inactivity were high. PA and BMI increased over time and were not impacted by an educational PA intervention. Findings provide important information for developing lifestyle interventions for young breast cancer survivors.
Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta‐analysis
Allen‐Rhoades, Wendy , Lupo, Philip J. , Kuttesch, John F., Venkatramani, Rajkumar , Meyer, William H. , Mascarenhas, Leo , Mascarenhas, Leo , Allen-Rhoades, Wendy A , Scheurer, Michael E. , Chi, Yueh‐Yun

Mayo Clinic

Cancer Medicine | April 5, 2023 | Volume: 12 | Issue: 9 | Pages: 10222-10229

10.1002/cam4.5749 | PMID 37016270 Get It

AbstractBackgroundPatients with alveolar rhabdomyosarcoma (ARMS) have inferior outcomes compared to patients with embryonal rhabdomyosarcoma (ERMS) and more effective chemotherapy options are needed for these patients. Vinorelbine is a semisynthetic vinca alkaloid that has clinical activity in relapsed rhabdomyosarcoma (RMS) when used alone or in combination with cyclophosphamide.AimsThe goal of our study was to evaluate whether RMS histology subtype influences response rate to vinorelbine alone or in combination.Materials & MethodsFive Phase 2 trials that enrolled RMS patients were included in the meta‐analysis. Two studies evaluated vinorelbine alone, two studies evaluated vinorelbine in combination with low dose oral cyclophosphamide, and one study evaluated vinorelbine and intravenous cyclophosphamide in combination with temsirolimus or bevacizumab. All RMS patients had relapsed or refractory disease and had received at least one prior therapy. Response was reported according to RECIST1.1 and was defined as a complete or partial response. Response data was obtained from published results or from trial principal investigator. RMS NOS patients were grouped with ERMS patients for this analysis. Summary estimates comparing differences between ARMS and ERMS response rates were generated using a random‐effects model to account for heterogeneity among the studies.ResultsOne hundred fifty‐six enrolled patients evaluable for response were included in the meta‐analysis, 85 ARMS, 64 ERMS and 7 RMS‐NOS. The combined effect generated from the random‐effects model demonstrated a 41% increase (p = 0.001, 95% CI; 0.21–0.60) in response to vinorelbine as a single agent or in combination in patients with ARMS compared to patients with ERMS. There was no significant difference in the rate of progressive disease between patients with ARMS compared to ERMS (p = 0.1, 95%CI; −0.26–0.02).DiscussionVinorelbine is an active agent for the treatment of relapsed or refractory RMS and a meta‐analysis of Phase 2 studies shows that radiographic responses in patients with ARMS were significantly higher than ERMS or RMS‐NOS.ConclusionThese data support further investigation of vinorelbine in newly diagnosed patients with RMS particularly those with alveolar histology.
Pregnancy programs epigenetic and transcriptional exhaustion in memory CD8+ T cells
Pollard, Jared M. , Hynes, Grace , Yin, Dengping , Mandal, Malay , Gounari, Fotini , Alegre, Maria‐Luisa , Gounari, Fotini , Chong, Anita S.

Mayo Clinic

No container title available | April 5, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2196637/v1 | PMID 37066154 Get It

Abstract Alloreactive memory T cells, unlike naive T cells, fail to be restrained by transplantation tolerance protocols or regulatory T cells, and therefore represent a critical barrier to long-term graft acceptance. Using female mice sensitized by rejection of fully-mismatched paternal skin allografts, we show that subsequent semi-allogeneic pregnancy successfully reprograms memory fetus/graft-specific CD8+ T cells (TFGS) towards hypofunction in a manner that is mechanistically distinct from naive TFGS. Post-partum memory TFGS were durably hypofunctional, exhibiting enhanced susceptibility to transplantation tolerance induction. Furthermore, multi-omics studies revealed that pregnancy induced extensive phenotypic and transcriptional modifications in memory TFGS reminiscent of T cell exhaustion. Strikingly, at loci transcriptionally modified in both naive and memory TFGS during pregnancy, chromatin remodeling was observed exclusively in memory and not naive TFGS. These data reveal a novel link between T cell memory and hypofunction via exhaustion circuits and pregnancy-mediated epigenetic imprinting. This conceptual advance has immediate clinical relevance to pregnancy and transplantation tolerance.
Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer
Venkatachalam, Annapoorna , McGehee, Cordelia D. , Finstuen-Magro, Sarah, VanBlaricom, Jamison L., Schneider, Paula A., Peterson, Kevin L. , Heinzen, Ethan P. , Hou, Xiaonon, Oberg, Ann L. , Weroha, Saravut J., Correia, Cristina , Finstuen-Magro, Sarah, Larson, Melissa C. , Kaufmann, Scott H.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5058-5058

10.1158/1538-7445.am2023-5058 Get It

Abstract Background: Ovarian cancer ranks fifth in cancer deaths among women. The gold standard of care for advanced disease includes cytoreductive surgery along with adjuvant or neoadjuvant platinum/taxane-based chemotherapy. Although response to this treatment is high, chemotherapy-induced nausea and vomiting due to platinum agents and allergic reactions due to both agents are common. For nearly half a century, the glucocorticoid (GC) dexamethasone (DEX) has been administered as part of supportive care. However, there have periodically been questions about the possible deleterious effects of DEX on chemotherapy response, especially in solid tumors. Methods: Platinum-sensitive, glucocorticoid receptor (GRα) expressing ovarian cancer cells were exposed to DEX prior to chemotherapy and clonogenic survival was assessed. The effects of DEX on cell cycle and apoptosis were assessed by flow cytometry. Changes in the tumor cell transcriptome after acute DEX treatment were determined by RNA sequencing. Mice bearing orthotopic ovarian cancer patient-derived xenografts (PDXs) were treated with chemotherapy ± DEX to assess changes in chemotherapy response in vivo. Findings: DEX pre-treatment decreased platinum cytotoxicity in ovarian cancer cell lines in vitro and diminished platinum response in some PDXs analyzed for chemotherapy response ex vivo. RNA-seq analysis revealed changes in transcripts encoding proteins involved in platinum detoxification and TNFα pro-survival signaling. In ovarian cancer PDXs, DEX decreased platinum response in one model and had limited impact on both platinum and platinum/taxane chemotherapy in three distinct studies. Interpretation: DEX appears to modulate chemotherapy response in some settings in vitro and ex-vivo. The impact of DEX on chemotherapy response in vivo appears to be limited. However, further investigation of this question in vivo in non-immunosuppressed murine models appears warranted. Citation Format: Annapoorna Venkatachalam, Cristina Correia, Cordelia D. Mcgehee, Sarah Finstuen-Magro, Jamison VanBlaricom, Paula A. Schneider, Kevin L. Peterson, Ethan P. Heinzen, Melissa C. Larson, Xiaonon Hou, Ann L. Oberg, Saravut John Weroha, Scott H. Kaufmann. Impact of dexamethasone on chemotherapy response in ovarian cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5058.
Abstract 5539: Assessing knowledge, vaccine hesitancy, and completion rates of free HPV vaccination in uninsured/underinsured low-income patients
Diaz, Hiram, Colón‐Otero, Gerardo , Casanova-Leyva, Sandra, Pacheco-Spann, Laura M. , DeStephano, Christopher C.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5539-5539

10.1158/1538-7445.am2023-5539 Get It

Abstract Background: Human Papillomavirus (HPV) vaccination rates remain low in the U.S., particularly among minorities and low-income patients. In 2014, a Mayo Clinic study of uninsured, low-income, working, Volunteer in Medicine (VIM) Clinic patients in Jacksonville, Florida found a statistically significant lower awareness of HPV (50.3% vs 63.6%) and the HPV vaccine (32.1% vs 62.7%) than the national population. As a result, our team collaborated with Merck to develop a free HPV vaccination program and video education campaign for VIM patients. Methods: We assessed VIM patients HPV vaccination knowledge, awareness, and prevalence of hesitancy towards receiving the vaccine. VIM patients (ages 18-45) with no previous history of HPV vaccination were invited to participate in this study. The Parents Attitudes about Childhood Vaccines (PACV) survey was used to evaluate vaccine hesitancy. Patients who declined the HPV vaccine were shown an educational video to assess effectiveness in persuading patients’ opinion. Each participant received a vaccine hesitancy PACV score, which was compared with their vaccine disposition. Mayo Clinic IRB approval of the study was obtained. Results: Our analysis included 43 patients (34 females, 9 males) with a median age of 40 (age range 27- 45). Patients had overall knowledge of HPV of 88.4%, with 69.8% having heard of the HPV vaccine. 85.7% PACV survey respondents were deemed non-hesitant (PACV scores 0-49), and 80.6% of the non-hesitant subset (29/36) agreed to undergo vaccination. The average PACV score of vaccine-interested participants was lower (25.2) than the average of participants not interested in the vaccine (36.7). Black participants had a statistically significant higher PACV score than White participants. The PACV scores of individuals who were already familiar with the HPV vaccine were significantly lower than those of participants who were unfamiliar with the HPV vaccine. Only 20% (2/10) of individuals, who had previously declined vaccination, agreed to receive the HPV vaccine after viewing the HPV educational video. Of the 33 participants who agreed to receive the free HPV vaccine, only 9 (27.3%) completed all three doses. Conclusions: HPV vaccine awareness and knowledge at VIM increased compared to the 2014 cohort. Vaccine hesitancy was not observed in most patients, yet video education was effective in only a small portion of patients with vaccine hesitancy. Additionally, a minority of patients who agreed to receive the free HPV vaccine series completed all three doses. Our results suggests that free HPV vaccination and video education is not sufficient to achieve adequate vaccination rates among low-income uninsured young adults, nor overcoming vaccine hesitancy. Innovative measures are warranted to improve vaccination rates in this population. Citation Format: Hiram Diaz, Gerardo Colon-Otero, Laura M. Pacheco-Spann, Christopher C. DeStephano, Sandra Casanova-Leyva. Assessing knowledge, vaccine hesitancy, and completion rates of free HPV vaccination in uninsured/underinsured low-income patients. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5539.
Abstract 723: Who reconstitutes my chemotherapy? Examining the educational needs of oncology pharmacy practitioners in Nigeria
Chidebe, Runcie C., Alabelewe, Ramatu Masud, Okwu, Gloria C., Emejulu, Jacinta, Umar, Adamu Abubakar , Okwuegbunam, Ndifreke, David, Funsho, Adepoju, Toyosi, Sapkota, Krishna Prasad , Agha, Agha A., Aruah, Simeon Chinedu , Graef, Katy, Duncombe, Rob, nwaneri, matthew Obinna, Wannang, Noel N., O’Bryant, Cindy L. , Babalola, Peace C., Odedina, Folakemi T., O'Bryant, Cindy , Esiaka, Darlingtina , Orjiakor, Charles Tochukwu , Lasebikan, Nwamaka , Umar, Adamu A., Nwakasi, Candidus C. , Mshelia, Richard, Harvey, R. Donald

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 723-723

10.1158/1538-7445.am2023-723 Get It

Abstract BackgroundNigeria has the highest cancer burden in Africa with 124,815 cancer cases and 78,899 cancer deaths in 2020. The limited number of oncology specialists, inaccessibility of essential cancer medicines like chemotherapies, and suboptimal delivery of cancer care lead to poor treatment outcomes. Oncology pharmacy (OP) practitioners are critical oncology professionals in the multidisciplinary team (MDT) for cancer treatment globally. In Nigeria, there is a limited number of OP practitioners providing services like reconstitution of chemotherapy, clinical research, safe use of biosafety cabinets, and monitoring of adverse drug reactions. Although the interest in oncology pharmacy is increasing, the educational needs, available skill sets, and directed training in oncology pharmacy across the nation are unknown. In this study, we examined the educational needs of OP practitioners and worked with the West African College of Pharmacy West African Postgraduate College of Pharmacists (WAPCP), Oncology Pharmacy Practitioners Association of Nigeria (OPPAN), and the International Society of Oncology Pharmacy Practitioners to upgrade the oncology pharmacy practice in Nigeria. MethodA cross-sectional study with a semi-structured questionnaire was done in 2021 with 39 pharmacists working in oncology centers across Nigeria. General descriptive statistics and qualitative analysis was performed. ResultsThere is no board-certified oncology pharmacist in Nigeria. More than 50% of the general pharmacists working in oncology centers are responsible for chemotherapy reconstitution. Understanding chemotherapy reconstitution (automation of chemotherapeutic mixing, use of radiopharmaceuticals, etc), use of biosafety cabinets, knowledge of pharmacology, designing treatment protocols, data management, immunotherapy delivery, and oncology clinical trials were some of the most significant educational needs of the OP practitioners in Nigeria. OP practitioners are lacking in most cancer centers and MDTs. ConclusionThere is an urgent need for a specialty postgraduate training programme in oncology pharmacy in Nigeria. This would help increase oncology clinical trials, improve delivery of cancer medicines, quality of care, and management of toxicities. The West African Postgraduate College of Pharmacists and OPPAN need appropriate training resources to develop an oncology pharmacy curriculum, promote the specialty and collaborate with global institutions for board certifications. Citation Format: Runcie C. Chidebe, Ramatu M. Alabelewe, Darlingtina K. Esiaka, Gloria C. Okwu, Tochukwu C. Orjiakor, Nwamaka Lasebikan, Jacinta Emejulu, Adamu A. Umar, Ndifreke Okwuegbunam, Funsho David, Toyosi Adepoju, Krishna Prasad Sapkota, Candidus C. Nwakasi, Agha A. Agha, Simeon C. Aruah, Katy Graef, Richard Mshelia, Rob Duncombe, Matthew O. Nwaneri, Noel Wannang, Cindy O’Bryant, R. Donald Harvey, Peace C. Babalola, Folakemi T. Odedina. Who reconstitutes my chemotherapy? Examining the educational needs of oncology pharmacy practitioners in Nigeria [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 723.